BiotechTube
Multitude Therapeutics

Multitude Therapeutics

Cambridge, United States· Est.
multitudetherapeutics.info
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Multitude Therapeutics is an early-stage biotech leveraging its unique MabArray platform for high-throughput target and antibody discovery. Founded in 2021 and headquartered in the biotech hub of Cambridge, USA, the company is in a pre-clinical, pre-revenue stage, positioning itself as a platform technology company. Its primary focus is on identifying novel biological targets and developing antibody-based therapeutics, though specific pipeline details and leadership are not publicly disclosed on its minimal website. The company appears to be privately held and in a foundational phase of technology validation and early asset development.

AntibodiesBiologics

Technology Platform

MabArray platform for high-throughput target and antibody discovery.

Funding History

1
Total raised:$60M
Series A$60M

Opportunities

The large and growing market for therapeutic antibodies provides a clear endpoint for validated discoveries.
A successful platform that efficiently generates novel targets with attached therapeutic candidates could be highly valuable for internal development or lucrative partnership deals with large pharma.

Risk Factors

High technical risk that the platform fails to deliver clinically relevant targets.
Significant funding risk as a pre-revenue startup in a competitive financing environment.
Intense competition from established antibody discovery technologies and companies.

Competitive Landscape

The antibody discovery and target identification field is highly competitive, featuring numerous companies with advanced platforms like phage/yeast display, single-cell genomics, and computational/AI-driven design. Multitude's MabArray must demonstrate unique advantages in speed, specificity, or the quality of its outputs to differentiate itself.

More companies in Biologics / Biosimilars →More companies in United States →